LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Analysis on status quo and related factors of delays in diagnosis and treatment of breast cancer in Ningxia Hui Autonomous Region.

    Wang, Yuchen / Bai, Zhoulan / Liu, Qingyuan / Yu, Hui / Tang, Zhenning / Liu, Xiang / Liu, Qilun

    Medicine

    2024  Volume 103, Issue 17, Page(s) e37826

    Abstract: This study aimed to explore factors contributing to the delays in the diagnosis and treatment of breast cancer (BC) in Ningxia Hui Autonomous Region. We conducted a cohort analysis of 1012 patients with BC diagnosed at the General Hospital of Ningxia ... ...

    Abstract This study aimed to explore factors contributing to the delays in the diagnosis and treatment of breast cancer (BC) in Ningxia Hui Autonomous Region. We conducted a cohort analysis of 1012 patients with BC diagnosed at the General Hospital of Ningxia Medical University between January 2018 and December 2019. Sociodemographic data were collected through questionnaires, and clinical data were gathered and analyzed from relevant databases. Furthermore, observations were made regarding delays in the diagnosis and treatment of BC, followed by an analysis of the correlations between patient delay and both sociological factors within the population and clinical factors specific to patients with BC. Subsequently, the factors associated with patient delay and system delay were examined using Cox regression analysis, along with the inclusion of neoadjuvant therapy. In the prevention and treatment of BC in Ningxia, the patient delay rate was 33.20%, the diagnosis delay rate was 17.89%, the treatment delay rate was 0.0099% and the system delay rate was 41.60%. There was a higher proportion of patient delay and system delay in aged patients (age ≥ 61 years) with rural registered permanent residence (RPR), multiple clinical symptoms (such as nipple spillage, axillary abnormalities, etc), a T4 tumor size classification, and the initial use of neoadjuvant therapy. Besides, significant positive correlations were observed between patient delay and system delay time with BC stage. Patients aged 51 to 60 and those with molecular types (Limanal1B: ki-67 > 14%, Limanal1B: HER-2 positive) were prone to patient delay, whereas molecular characteristics influenced system delay, unrelated to sociodemographic factors. The study identifies significant age, residency, and tumor molecular subtype correlations with diagnostic and treatment delays in Ningxia's patients with BC, predominantly affecting women aged 41 to 60, especially urban dwellers. These findings underscore the need for targeted interventions to reduce delays and improve BC care in this region.
    MeSH term(s) Humans ; Breast Neoplasms/therapy ; Breast Neoplasms/diagnosis ; Female ; Middle Aged ; Time-to-Treatment/statistics & numerical data ; Delayed Diagnosis/statistics & numerical data ; China/epidemiology ; Adult ; Aged ; Neoadjuvant Therapy/statistics & numerical data ; Neoadjuvant Therapy/methods ; Age Factors
    Language English
    Publishing date 2024-04-26
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 80184-7
    ISSN 1536-5964 ; 0025-7974
    ISSN (online) 1536-5964
    ISSN 0025-7974
    DOI 10.1097/MD.0000000000037826
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Exploring thyroxine binding globulin structural changes and its release from human hepatoblastoma cells upon interaction with silica particles: A prelude to unrevealing the mechanism of thyroid hormone dysregulation

    Wang, Meiqi / Wang, Yu-Chen / Bai, Zhou-Lan / Sui, Yang / Yin, Detao / Yin, Hua

    International Journal of Biological Macromolecules. 2023, p.126240-

    2023  , Page(s) 126240–

    Abstract: Endocrine dysregulation in the presence of environmental chemical risk factors is a global adverse health concern. The aim of this investigation was to explore the structural changes and binding affinity of thyroxine (T4) binding protein (TBG) upon ... ...

    Abstract Endocrine dysregulation in the presence of environmental chemical risk factors is a global adverse health concern. The aim of this investigation was to explore the structural changes and binding affinity of thyroxine (T4) binding protein (TBG) upon interaction with SiO₂ particles as the second largest mineral in the Earth's crust and one of the most important constituents of rock, soil, and dust. Therefore, the interaction of TBG with SiO₂ particles was assessed by fluorescence quenching, molecular docking, ANS and synchronous fluorescence, and far-UV CD analyses. Also, the release of TBG from human hepatoblastoma cell line, Hep G2, was assessed by ELISA assay. The results indicated that the value of stoichiometry of binding site (n) of TBG for T4 was approximately equal to one, which was reduced to 0.36 in the presence of SiO₂ particles. Also, the binding affinity (Kb) values indicated that the binding affinity between T4 and TBG was strong (97.90 × 10⁵ L/mol), while the presence of SiO₂ particles resulted in the calculation of a Kb around 0.00159 × 10⁵ L/mol, which was significantly lower than that of the absence of SiO₂ particles. This data was also verified by molecular docking study which indicated that SiO₂ particles interacted with the T4 binding pocket of TBG. Moreover, further studies exhibited that although the equimolar concentration of T4 to TBG resulted in the superior stability of TBG-T4 complex relative to free TBG, the presence of SiO₂ particles with the same concentration led to denaturation of the secondary structure of TBG. Furthermore, it was seen that the amount of released TBG in the cell culture medium of Hep G2 was about 2.21 ng/ml protein, whereas this amount in SiO₂ particles-treated cell group was significantly reduced to 1.71 ng/ml protein (*P < 0.05). In conclusion, this study implies that SiO₂ particles show the potential to result in inhibition of TBG release, TBG denaturation, and interfere with TBG binding affinity which may lead to dysregulation of the thyroid hormone transport and associated signaling pathways.
    Keywords cell culture ; cell lines ; culture media ; denaturation ; dust ; fluorescence ; globulins ; humans ; risk ; silica ; soil ; stoichiometry ; thyroid hormones ; thyroxine ; ultraviolet radiation ; Thyroxine binding globulin ; Silica particle ; Interaction ; Protein release ; Thyroid hormone transport
    Language English
    Publishing place Elsevier B.V.
    Document type Article ; Online
    Note Pre-press version
    ZDB-ID 282732-3
    ISSN 1879-0003 ; 0141-8130
    ISSN (online) 1879-0003
    ISSN 0141-8130
    DOI 10.1016/j.ijbiomac.2023.126240
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  3. Article ; Online: Exploring thyroxine binding globulin structural changes and its release from human hepatoblastoma cells upon interaction with silica particles: A prelude to unrevealing the mechanism of thyroid hormone dysregulation.

    Wang, Meiqi / Wang, Yu-Chen / Bai, Zhou-Lan / Sui, Yang / Yin, Detao / Yin, Hua

    International journal of biological macromolecules

    2023  Volume 251, Page(s) 126240

    Abstract: Endocrine dysregulation in the presence of environmental chemical risk factors is a global adverse health concern. The aim of this investigation was to explore the structural changes and binding affinity of thyroxine (T4) binding protein (TBG) upon ... ...

    Abstract Endocrine dysregulation in the presence of environmental chemical risk factors is a global adverse health concern. The aim of this investigation was to explore the structural changes and binding affinity of thyroxine (T4) binding protein (TBG) upon interaction with SiO
    Language English
    Publishing date 2023-08-09
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 282732-3
    ISSN 1879-0003 ; 0141-8130
    ISSN (online) 1879-0003
    ISSN 0141-8130
    DOI 10.1016/j.ijbiomac.2023.126240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).

    Ding, Xiao-Long / Su, Yi-Ge / Yu, Liang / Bai, Zhou-Lan / Bai, Xue-Hong / Chen, Xiao-Zhen / Yang, Xia / Zhao, Ren / He, Jin-Xi / Wang, Yan-Yang

    World journal of surgical oncology

    2022  Volume 20, Issue 1, Page(s) 54

    Abstract: Background: Recent studies have shown that according to the expression levels of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3), small cell lung cancer (SCLC) can be divided into four ... ...

    Abstract Background: Recent studies have shown that according to the expression levels of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3), small cell lung cancer (SCLC) can be divided into four subtypes: SCLC-A (ASCL1-dominant), SCLC-N (NEUROD1-dominant), SCLC-P (POU2F3-dominant), and SCLC-I (triple negative or SCLC-inflamed). However, there are limited data on the clinical characteristics and prognosis of molecular subtypes of SCLC.
    Methods: Immunohistochemistry (IHC) was used to detect the expression levels of ASCL1, NEUROD1, and POU2F3 in 53 patient samples of resectable SCLC. The subtype was defined by the differential expression of the transcription factors for ASCL1, NEUROD1, and POU2F3 or the low expression of all three factors with an inflamed gene signature (SCLC-A, SCLC-N, SCLC-P, and SCLC-I, respectively). The clinicopathological characteristics, immunological features (programmed death ligand 1 [PD-L1] expression and CD8+ tumor infiltrating lymphocyte [TIL] density), and patient outcomes of the four subtypes of SCLC were analyzed.
    Results: Positive ASCL1, NEUROD1, and POU2F3 staining was detected in 43 (79.2%), 27 (51.0%), and 17 (32.1%) SCLC specimens by IHC. According to the results of IHC analysis, SCLC was divided into four subtypes: SCLC-A (39.6%), SCLC-N (28.3%), SCLC-P (17.0%), and SCLC-I (15.1%). The 5-year overall survival (OS) rates of these four subtypes were 61.9%, 69.3%, 41.7%, and 85.7%, respectively (P=0.251). There were significant differences in smoking status among different subtypes of SCLC (P= 0.031). However, we did not confirm the correlation between subtypes of SCLC and other clinicopathological factors or immune profiles. Cox multivariate analysis showed that N stage (P=0.025), CD8+ TILs (P=0.024), Ki-67 level (P=0.040), and SCLC-P (P=0.023) were independent prognostic factors for resectable SCLC.
    Conclusions: Our IHC-based study validated the proposed classification of SCLC using the expression patterns of key transcriptional regulatory factors. We found that SCLC-P was associated with smokers and was one of the poor prognostic factors of limited-stage SCLC. In addition, no correlation was found between PD-L1 expression or CD8+ TIL density and SCLC subtypes.
    MeSH term(s) Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms/genetics ; Prognosis ; Small Cell Lung Carcinoma/genetics ; Small Cell Lung Carcinoma/surgery ; Transcription Factors/genetics
    Chemical Substances Transcription Factors
    Language English
    Publishing date 2022-02-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2118383-1
    ISSN 1477-7819 ; 1477-7819
    ISSN (online) 1477-7819
    ISSN 1477-7819
    DOI 10.1186/s12957-022-02528-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation.

    Zhou, Shun / Bai, Zhou-Lan / Xia, Di / Zhao, Zhi-Jun / Zhao, Ren / Wang, Yan-Yang / Zhe, Hong

    Molecular carcinogenesis

    2018  Volume 57, Issue 5, Page(s) 590–597

    Abstract: The role of ... ...

    Abstract The role of N
    MeSH term(s) Adenosine/analogs & derivatives ; Adenosine/metabolism ; Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics ; Animals ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/pathology ; Cell Line, Tumor ; Chemoradiotherapy ; DNA-Binding Proteins/metabolism ; Demethylation ; Drug Resistance, Neoplasm ; Endonucleases/metabolism ; Female ; Humans ; Mice ; Neoplasm Transplantation ; Prognosis ; Radiation Tolerance ; Survival Analysis ; Up-Regulation ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/metabolism ; Uterine Cervical Neoplasms/pathology ; beta Catenin/genetics
    Chemical Substances CTNNB1 protein, human ; DNA-Binding Proteins ; beta Catenin ; N-methyladenosine (CLE6G00625) ; Alpha-Ketoglutarate-Dependent Dioxygenase FTO (EC 1.14.11.33) ; FTO protein, human (EC 1.14.11.33) ; ERCC1 protein, human (EC 3.1.-) ; Endonucleases (EC 3.1.-) ; Adenosine (K72T3FS567)
    Language English
    Publishing date 2018-02-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1004029-8
    ISSN 1098-2744 ; 0899-1987
    ISSN (online) 1098-2744
    ISSN 0899-1987
    DOI 10.1002/mc.22782
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma

    Bai Zhou-lan / Wang Yan-yang / Zhe Hong / He Jian-li / Hai Ping

    Radiation Oncology, Vol 7, Iss 1, p

    2012  Volume 221

    Abstract: Abstract Background The purpose of this study was to investigate whether the excision repair cross-complementation group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical squamous cell carcinoma (LACSCC) ...

    Abstract Abstract Background The purpose of this study was to investigate whether the excision repair cross-complementation group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical squamous cell carcinoma (LACSCC) who underwent cisplatin-based concurrent chemoradiotherapy (CCCRT). Methods A total of sixty LACSCC patients, treated with radical CCCRT from a single institution were evaluated. ERCC1 mRNA expression was determined by quantitative real-time RT-PCR in pre-treatment tumor tissues. The association of ERCC1 status with clinicopathological characteristics (age, histological grade, tumor size, parametrial invasion, lymph node metastasis and FIGO stage) and treatment response were analyzed. Results No significant association between ERCC1 mRNA expression and clinicopathological characteristics were observed. Patients with low ERCC1 mRNA level had a significantly higher rate of complete response (86.21%) than patients with high level of ERCC1 expression (19.36%; p < 0.001). In the logistic regression analysis, low ERCC1 mRNA level retained an independent role in predicting complete response to CCCRT ( P < 0.001). An ERCC1 expression level of 0.0901 was determined as an optimal cutoff value to identify complete response patients to CCCRT treatment. The sensitivity for detection of a complete response was 81.48% with a specificity of 96.97% (area under the curve, 0.893; 95% confidence interval, 0.804–0.983). Conclusions This is the first analysis of the association between ERCC1 mRNA levels and treatment response in patients with LACSCC. Low ERCC1 mRNA level appears to be a highly specific predictor of response to CCCRT in LACSCC.
    Keywords Excision repair cross-complementation group 1 (ERCC1) ; Cervical squamous cell carcinoma ; Chemoradiotherapy ; Response prediction ; Medical physics. Medical radiology. Nuclear medicine ; R895-920 ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282
    Subject code 610 ; 616
    Language English
    Publishing date 2012-12-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy.

    Wang, Yan-Yang / Bai, Zhou-Lan / He, Jian-Li / Yang, Yan / Zhao, Ren / Hai, Ping / Zhe, Hong

    Disease markers

    2016  Volume 2016, Page(s) 3740794

    Abstract: The aim of this study was to explore the relationship between neutrophil-related factors, including neutrophil-lymphocyte ratio (NLR) and the responses of neutrophil to granulocyte colony-stimulating factors (RNG), and the prognosis of patients with ... ...

    Abstract The aim of this study was to explore the relationship between neutrophil-related factors, including neutrophil-lymphocyte ratio (NLR) and the responses of neutrophil to granulocyte colony-stimulating factors (RNG), and the prognosis of patients with locally advanced cervical squamous cell carcinoma (LACSCC) undergoing cisplatin-based concurrent chemoradiotherapy (CCCRT). A total of sixty LACSCC patients were enrolled in this study. We analyzed the association of NLR or RNG with clinicopathologic characteristics of these patients. The prognostic factors were evaluated by univariate and multivariate survival analysis. The optimal cut-off value of the NLR was determined to be 2.0 for the overall survival (OS). A higher level of the NLR was associated with younger age (P = 0.017) and higher baseline platelet count (P = 0.040). NLR was identified to be the only independent prognostic factor for OS by multivariate analysis (P = 0.037). The median RNG was 3.01, with a range of 1.19-16.84. RNG level was significantly associated with lymph node metastasis of these patients (P = 0.023). And higher RNG was identified as being a closely independent poor prognostic factor for OS (P = 0.055). This study showed that NLR and RNG may be used as potential biomarkers for survival prediction in patients with LACSCC receiving CCCRT.
    MeSH term(s) Adult ; Age Factors ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/therapy ; Chemoradiotherapy ; Cisplatin/administration & dosage ; Cisplatin/therapeutic use ; Female ; Humans ; Lymphatic Metastasis ; Lymphocyte Count ; Middle Aged ; Neutrophils/immunology ; Prognosis ; Survival Analysis ; Treatment Outcome ; Uterine Cervical Neoplasms/immunology ; Uterine Cervical Neoplasms/mortality ; Uterine Cervical Neoplasms/therapy
    Chemical Substances Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2016
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604951-5
    ISSN 1875-8630 ; 0278-0240
    ISSN (online) 1875-8630
    ISSN 0278-0240
    DOI 10.1155/2016/3740794
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.

    Bai, Zhou-lan / Wang, Yan-yang / Zhe, Hong / He, Jian-li / Hai, Ping

    Radiation oncology (London, England)

    2012  Volume 7, Page(s) 221

    Abstract: Background: The purpose of this study was to investigate whether the excision repair cross-complementation group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical squamous cell carcinoma (LACSCC) who ... ...

    Abstract Background: The purpose of this study was to investigate whether the excision repair cross-complementation group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical squamous cell carcinoma (LACSCC) who underwent cisplatin-based concurrent chemoradiotherapy (CCCRT).
    Methods: A total of sixty LACSCC patients, treated with radical CCCRT from a single institution were evaluated. ERCC1 mRNA expression was determined by quantitative real-time RT-PCR in pre-treatment tumor tissues. The association of ERCC1 status with clinicopathological characteristics (age, histological grade, tumor size, parametrial invasion, lymph node metastasis and FIGO stage) and treatment response were analyzed.
    Results: No significant association between ERCC1 mRNA expression and clinicopathological characteristics were observed. Patients with low ERCC1 mRNA level had a significantly higher rate of complete response (86.21%) than patients with high level of ERCC1 expression (19.36%; p < 0.001). In the logistic regression analysis, low ERCC1 mRNA level retained an independent role in predicting complete response to CCCRT (P < 0.001). An ERCC1 expression level of 0.0901 was determined as an optimal cutoff value to identify complete response patients to CCCRT treatment. The sensitivity for detection of a complete response was 81.48% with a specificity of 96.97% (area under the curve, 0.893; 95% confidence interval, 0.804-0.983).
    Conclusions: This is the first analysis of the association between ERCC1 mRNA levels and treatment response in patients with LACSCC. Low ERCC1 mRNA level appears to be a highly specific predictor of response to CCCRT in LACSCC.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Biomarkers, Pharmacological/analysis ; Biomarkers, Pharmacological/metabolism ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carcinoma, Squamous Cell/diagnosis ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/therapy ; Chemoradiotherapy/methods ; Cisplatin/administration & dosage ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; DNA-Binding Proteins/physiology ; Disease Progression ; Endonucleases/genetics ; Endonucleases/metabolism ; Endonucleases/physiology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Middle Aged ; Prognosis ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Treatment Outcome ; Uterine Cervical Neoplasms/diagnosis ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/therapy
    Chemical Substances Biomarkers, Pharmacological ; Biomarkers, Tumor ; DNA-Binding Proteins ; RNA, Messenger ; ERCC1 protein, human (EC 3.1.-) ; Endonucleases (EC 3.1.-) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2012-12-23
    Publishing country England
    Document type Evaluation Study ; Journal Article
    ISSN 1748-717X
    ISSN (online) 1748-717X
    DOI 10.1186/1748-717X-7-221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top